Verastem Inc Dossier - Source-backed chat

Verastem Inc

VSTMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.05Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $729M

Enterprise Value $633.4M

Shares Outstanding 100.8M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Verastem, Inc. (VSTM) presents a compelling high-risk, high-reward investment opportunity in the oncology space. The company has successfully transitioned to a commercial-stage entity with the U.S. launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). While the commercial franchise is expected to become self-sustaining in the second half of 2026, the primary driver of long-term shareholder value is Verastem's robust clinical pipeline. Specifically, the oral KRAS G12D inhibitor VS-7375 has demonstrated best-in-class potential, recently securing FDA Fast Track Designation and advancing into registration-directed Phase 2 trials. Although the company faces near-term financial pressure and going concern risks due to rising R&D expenses, positive clinical catalysts and strategic flexibility support a bullish outlook.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$14.75

High · most bullish analyst$18.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commercial adoption of the CO-PACK slows down, failing to reach self-sustainability in 2026. VS-7375 Phase 2 trials encounter safety issues or disappointing efficacy, undermining its competitive positioning against rival KRAS G12D inhibitors. The company is forced to execute highly dilutive equity financing under unfavorable market conditions to address its going concern status.

Base CaseCentral scenario

The commercial franchise of AVMAPKI FAKZYNJA CO-PACK continues to grow steadily, achieving self-sustainability in H2 2026. VS-7375 successfully advances through its Phase 2 registration-directed trials (TARGET-D 201, 202, and 203) with positive safety and efficacy readouts, confirming its best-in-class profile. Verastem secures a strategic partnership or non-dilutive financing to address its going concern risk and extend its cash runway beyond H1 2027.

Bull CaseUpside scenario

Verastem Oncology's bull case is driven by the successful commercial launch of AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib), which received FDA accelerated approval in May 2025 as the first-ever treatment specifically approved for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). This commercial revenue stream is expected to make the LGSOC program self-sustaining by the second half of 2026. Additionally, the company's pipeline features VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, which has initiated three Phase 2 registration-directed trials (TARGET-D 201, 202, and 203) across pancreatic, non-small cell lung, and colorectal cancers, supported by a solid cash runway extending into the first half of 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Commercial validation with the FDA-approved AVMAPKI FAKZYNJA CO-PACK for recurrent LGSOC.
Promising pipeline led by VS-7375, a potential best-in-class oral KRAS G12D inhibitor with FDA Fast Track Designation.
Strong clinical data from the RAMP 205 trial in first-line metastatic pancreatic cancer, showing an 86% 6-month overall survival rate.
Strategic flexibility to pursue global partnerships and non-dilutive funding options.

Key Investment Risks

Going concern risk highlighted in the Q1 2026 10-Q filing due to a substantial increase in projected Phase 2 R&D expenses.
High cash burn rate with cash, cash equivalents, and investments of $181.7 million only expected to fund operations into H1 2027.
Clinical development risks, including potential safety signals or insufficient efficacy in ongoing trials.
Intense competition in the RAS/MAPK pathway-driven cancer space from larger biopharmaceutical companies.

Thesis Invalidation Triggers

Failure of VS-7375 to meet primary endpoints in the TARGET-D Phase 2 trials.
Inability to secure additional financing or strategic partnerships, leading to severe liquidity constraints.
Regulatory delays or rejection of the planned NDA submission for the LGSOC combination therapy by the end of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.